FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4253588002> ?p ?o ?g. }

• W4253588002 endingPage "1211" @default.
• W4253588002 startingPage "1205" @default.
• W4253588002 abstract "Disease relapse and transplant related toxicities have limited the application of bone marrow transplantation (BMT) in the treatment for hematologic malignancies. Because elevated levels of tumor necrosis factor alpha (TNF-alpha) have been correlated with the development of transplant related complications, we conducted a phase I-II trial of pentoxifylline (PTX), a xanthine derivative capable of down-regulating TNF-alpha production, in patients with hematologic malignancies undergoing BMT. Thirty consecutive adult patients (median age, 34) were entered and received either an allogeneic (n = 26) or autologous (n = 4) BMT. Patients were enrolled at increasing dose levels (1,200, 1,600, and 2,000 mg/d) from day -10 through day +100 posttransplant. PTX was well tolerated with no significant adverse side effects noted at any of the dose levels administered. The actuarial day 100 survival for these 30 patients was 90% (95% confidence interval 79% to 100%). When compared with a good risk control group, PTX recipients experienced less mucositis (3.7 +/- 1.1 v 18.7 +/- 1.1 days, P = .004), less hepatic venocclusive disease (10% v 65%, P = .001), a lower incidence of renal insufficiency (3% v 65%, P = .0003), required less days of total parenteral nutrition (TPN) (24.0 +/- 1.3 v 35.0 +/- 2.4, P = .001) and were discharged from the hospital earlier than controls (day 26.0 +/- 1.8 v 37.0 +/- 3.8, P = .01). In addition the incidence of graft-versus-host disease (GVHD) greater than or equal to grade II was also reduced among the PTX recipients (35% v 68%, P = .03). PTX at doses in excess of 1,200 mg/d further reduced the severity of mucositis, and TPN requirements resulting in earlier hospital discharge than patients receiving 1,200 mg/d of PTX. In this study oral administration of PTX in doses up to 2,000 mg/d was well tolerated and associated with a reduction in morbidity and mortality in patients undergoing BMT. Prospective randomized trials are currently in progress to test these preliminary observations." @default.
• W4253588002 created "2022-05-12" @default.
• W4253588002 creator A5035506242 @default.
• W4253588002 creator A5042362307 @default.
• W4253588002 creator A5053741099 @default.
• W4253588002 creator A5060323697 @default.
• W4253588002 creator A5066922931 @default.
• W4253588002 creator A5068311742 @default.
• W4253588002 creator A5078882660 @default.
• W4253588002 creator A5088078568 @default.
• W4253588002 date "1991-09-01" @default.
• W4253588002 modified "2023-10-14" @default.
• W4253588002 title "Phase I-II trial of pentoxifylline for the prevention of transplant- related toxicities following bone marrow transplantation [published erratum appears in Blood 1992 Jun 15;79(12):3397] [see comments]" @default.
• W4253588002 doi "https://doi.org/10.1182/blood.v78.5.1205.bloodjournal7851205" @default.
• W4253588002 hasPublicationYear "1991" @default.
• W4253588002 type Work @default.
• W4253588002 citedByCount "1" @default.
• W4253588002 crossrefType "journal-article" @default.
• W4253588002 hasAuthorship W4253588002A5035506242 @default.
• W4253588002 hasAuthorship W4253588002A5042362307 @default.
• W4253588002 hasAuthorship W4253588002A5053741099 @default.
• W4253588002 hasAuthorship W4253588002A5060323697 @default.
• W4253588002 hasAuthorship W4253588002A5066922931 @default.
• W4253588002 hasAuthorship W4253588002A5068311742 @default.
• W4253588002 hasAuthorship W4253588002A5078882660 @default.
• W4253588002 hasAuthorship W4253588002A5088078568 @default.
• W4253588002 hasBestOaLocation W42535880021 @default.
• W4253588002 hasConcept C120665830 @default.
• W4253588002 hasConcept C121332964 @default.
• W4253588002 hasConcept C126322002 @default.
• W4253588002 hasConcept C141071460 @default.
• W4253588002 hasConcept C197934379 @default.
• W4253588002 hasConcept C2776694085 @default.
• W4253588002 hasConcept C2778496288 @default.
• W4253588002 hasConcept C2779972918 @default.
• W4253588002 hasConcept C2780007613 @default.
• W4253588002 hasConcept C2780404050 @default.
• W4253588002 hasConcept C2911091166 @default.
• W4253588002 hasConcept C61511704 @default.
• W4253588002 hasConcept C71924100 @default.
• W4253588002 hasConcept C90924648 @default.
• W4253588002 hasConceptScore W4253588002C120665830 @default.
• W4253588002 hasConceptScore W4253588002C121332964 @default.
• W4253588002 hasConceptScore W4253588002C126322002 @default.
• W4253588002 hasConceptScore W4253588002C141071460 @default.
• W4253588002 hasConceptScore W4253588002C197934379 @default.
• W4253588002 hasConceptScore W4253588002C2776694085 @default.
• W4253588002 hasConceptScore W4253588002C2778496288 @default.
• W4253588002 hasConceptScore W4253588002C2779972918 @default.
• W4253588002 hasConceptScore W4253588002C2780007613 @default.
• W4253588002 hasConceptScore W4253588002C2780404050 @default.
• W4253588002 hasConceptScore W4253588002C2911091166 @default.
• W4253588002 hasConceptScore W4253588002C61511704 @default.
• W4253588002 hasConceptScore W4253588002C71924100 @default.
• W4253588002 hasConceptScore W4253588002C90924648 @default.
• W4253588002 hasIssue "5" @default.
• W4253588002 hasLocation W42535880021 @default.
• W4253588002 hasOpenAccess W4253588002 @default.
• W4253588002 hasPrimaryLocation W42535880021 @default.
• W4253588002 hasRelatedWork W2015416409 @default.
• W4253588002 hasRelatedWork W2276435695 @default.
• W4253588002 hasRelatedWork W2395544729 @default.
• W4253588002 hasRelatedWork W2400961336 @default.
• W4253588002 hasRelatedWork W2477069154 @default.
• W4253588002 hasRelatedWork W2983332991 @default.
• W4253588002 hasRelatedWork W2985550035 @default.
• W4253588002 hasRelatedWork W3029997219 @default.
• W4253588002 hasRelatedWork W4253588002 @default.
• W4253588002 hasRelatedWork W2521952050 @default.
• W4253588002 hasVolume "78" @default.
• W4253588002 isParatext "false" @default.
• W4253588002 isRetracted "false" @default.
• W4253588002 workType "article" @default.